Skip to main content

Main menu

  • Home
  • Content
    • First Release
    • Current
    • Archives
    • Collections
    • AV Rheum
  • Resources
    • Guide for Authors
    • Submit Manuscript
    • Author Payment
    • Reviewers
    • Advertisers
    • Classified Ads
    • Reprints and Translations
    • Permissions
    • Meetings
    • FAQ
    • Policies
  • Subscribers
    • Subscription Information
    • Purchase Subscription
    • Your Account
    • Terms and Conditions
  • About Us
    • About Us
    • Editorial Board
    • Letter from the Editor
    • Duncan A. Gordon Award
    • Accessibility
  • Contact Us
  • JRheum Supplements
  • Services

User menu

  • My Cart
  • Log In

Search

  • Advanced search
The Journal of Rheumatology
  • JRheum Supplements
  • Services
  • My Cart
  • Log In
The Journal of Rheumatology

Advanced Search

  • Home
  • Content
    • First Release
    • Current
    • Archives
    • Collections
    • AV Rheum
  • Resources
    • Guide for Authors
    • Submit Manuscript
    • Author Payment
    • Reviewers
    • Advertisers
    • Classified Ads
    • Reprints and Translations
    • Permissions
    • Meetings
    • FAQ
    • Policies
  • Subscribers
    • Subscription Information
    • Purchase Subscription
    • Your Account
    • Terms and Conditions
  • About Us
    • About Us
    • Editorial Board
    • Letter from the Editor
    • Duncan A. Gordon Award
    • Accessibility
  • Contact Us
  • Follow jrheum on Twitter
  • Visit jrheum on Facebook
  • Follow jrheum on LinkedIn
  • Follow jrheum on RSS
LetterLetter

Complement C5-blocking Agent in Refractory Dermatomyositis

STANISLAS FAGUER, JULIE BELLIERE and DAVID RIBES
The Journal of Rheumatology December 2018, 45 (12) 1710-1711; DOI: https://doi.org/10.3899/jrheum.180060
STANISLAS FAGUER
Département de Néphrologie et Transplantation d’organes, and Centre de référence des maladies rénales rares, Centre Hospitalier de Toulouse;
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • ORCID record for STANISLAS FAGUER
  • For correspondence: faguer.s@chu-toulouse.fr
JULIE BELLIERE
Département de Néphrologie et Transplantation d’organes, and Centre de référence des maladies rénales rares, Centre Hospitalier de Toulouse;
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
DAVID RIBES
Département de Néphrologie et Transplantation d’organes, and Centre de référence des maladies rénales rares, Centre Hospitalier de Toulouse.
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • Article
  • Figures & Data
  • References
  • Info & Metrics
  • PDF
  • eLetters
PreviousNext
Loading

To the Editor:

Dermatomyositis (DM) is a rare autoimmune disease that belongs to the group of idiopathic inflammatory myopathies (IIM). The usual treatment of DM was based on steroids, methotrexate, and azathioprine. Intravenous immunoglobulin (IVIG), rituximab (RTX), or other biological treatments recently emerged as steroid-sparing agents1. About 10% to 30% of patients will develop a refractory or chronic persistent disease2, suggesting that alternative treatments should be tested. Here, we report a case of acute refractory DM with concomitant thrombotic microangiopathy (TMA) that improved with the C5-blocking agent eculizumab in the setting of other medications. According to the French law regarding observational retrospective studies (Jardé Law, 2016), written informed consent to publish the material was obtained from the patient, but approval by a specific ethics board was waived.

A 19-year-old female patient, without medical history or medications, developed moderate arm and limb muscle weakness, Raynaud phenomenon, Gottron papules, mechanic’s hand, and edema of limb, arm, and periorbital regions. One month later, she was admitted to the hospital for severe acrocyanosis (Figure 1A–B), and examination showed elevated muscle enzymes [creatine kinase (CK) 11.243 IU/l, myoglobin 10.152 ng/ml, troponin 7.404 ng/l]. Cardiac magnetic resonance imaging (MRI) showed left ventricle hypertrophy and pericardial effusion suggestive of myocarditis, but breath-related artifacts precluded definitive diagnosis. Capillaroscopy demonstrated abnormal tortuous nailfold capillaries. Immunological tests showed only low serum complement C3/C4 components and increased soluble C5b-9 (Supplementary Table 1, available from the authors on request), but no antinuclear antibodies and myositis-specific autoantibodies. Neuromuscular biopsy showed perivascular and perimysial infiltration of nonnecrotic muscle fibers with CD4+ T cell and CD68+ macrophages, MHC-1 antigen expression close to the inflammatory infiltrates, and focal perifascicular atrophy suggestive of seronegative DM3. At that time, she had arthralgia but no arthritis, dysphagia, or interstitial lung disease. Skin biopsy and muscular MRI were not performed. Diagnosis of DM was retained according to the Bohan and Peter criteria (skin lesions and 3 out of 4 major criteria)4. Methylprednisolone (2 mg/kg/day) was started and IVIG was added at Day 3 because of persistent pain and edema of the legs, arms, and face, and elevated CK.

Figure 1.
  • Download figure
  • Open in new tab
  • Download powerpoint
Figure 1.

A and B. Severe acrocyanosis of the fingers and toes, with Gottron papules and scleroderma. C. Kinetics of CPK (red; IU/l), myoglobin (green; ng/ml), and troponin (blue, ng/l). IVIg: intravenous immunoglobulins; CPK: creatine phosphokinase; PEx: plasma exchange.

At Day 4, the patient was referred to our intensive care unit (ICU) for acute kidney injury with glomerular presentation (serum creatinine 278 μmol/l, protein-to-creatinine ratio 2.9 g/g, hematuria, hypertension) and features of TMA (hemolytic anemia, thrombocytopenia, decreased haptoglobin, lactate dehydrogenase increase, and circulating schizocytes). Search for anti-ADAMTS13, anticardiolipins, and anti-β2-GPI antibodies and genetic analysis of complement genes was negative. ADAMTS13 activity was within normal ranges (58%). IVIG were withdrawn. Despite daily plasma exchanges from Day 4 to Day 8, the patient developed extensive severe acrocyanosis, anuria, and status epilepticus, prompting us to use salvage therapy by eculizumab (Day 8; 900 mg weekly for 1 month, then followed by 1200 mg every 14 days) after pneumococcal and meningococcal vaccination5. Antibioprophylaxis by ceftriaxone was also started and steroids were maintained. Plasma exchanges were stopped.

As shown in Figure 1C, whereas CK and myoglobin levels were slightly or not modified by steroids, IVIG, and plasma exchanges, the first infusion of eculizumab was followed by a dramatic control of the muscle edema and myalgia. It was also followed by a complete reversal of the distal cyanosis and rapid decline in CK and myoglobin levels. Despite the lack of myositis-specific autoantibodies, RTX was given from days 18 to 40 (375 mg/m2 weekly).

Mechanical ventilation and dialysis were withdrawn at days 21 and 28, respectively. Eculizumab was stopped at Month 4 and RTX 500 mg was infused every 6 months. Six months after the admission to the ICU, serum creatinine was 80 μmol/l, and proteinuria and hematuria were negative. Hypertension was controlled using angiotensin-converting enzyme inhibitor. CK and myoglobin were in normal ranges and the patient did not report muscle weakness. Skin examination was normal. Search for neoplasia was negative.

Data from pathological studies suggest that DM is characterized by an antigen activation of the C5b9 macrophage-activating complex and deposition on the surface of the endothelial cells, with subsequent capillary ischemia and rarefaction, and CD4+ T cells infiltration6,7. Primary and secondary hemolytic and uremic syndromes (HUS), forms of TMA, are also characterized by an uncontrolled activation of the alternative complement pathway. Interestingly, a case of HUS was previously described in a patient with an IIM8, reinforcing the potential link between IIM and HUS forms of TMA. In contrast, direct involvement of skeletal muscle is rare in patients with TMA9. In this case, we successfully used eculizumab as a salvage therapy for a refractory HUS/TMA10, with concomitant severe DM. Other immunosuppressive agents helped to control the DM, but the almost complete normalization of the CK level after the first 2 infusions of eculizumab (before the use of RTX), contrasting with the lack of rapid response following steroids and plasma exchange, strongly suggested that eculizumab was an effective treatment to add-on in severe DM. This finding was similar to that of a previous study that included 10 patients with refractory DM11.

Our case suggests that C5 blocking should be tested in life-threatening or refractory DM.

REFERENCES

  1. 1.↵
    1. Leclair V,
    2. Lundberg IE
    . Recent clinical trials in idiopathic inflammatory myopathies. Curr Opin Rheumatol 2017;29:652–9.
    OpenUrl
  2. 2.↵
    1. Oddis CV,
    2. Reed AM,
    3. Aggarwal R,
    4. Rider LG,
    5. Ascherman DP,
    6. Levesque MC,
    7. et al.
    Rituximab in the treatment of refractory adult and juvenile dermatomyositis and adult polymyositis: a randomized, placebo-phase trial. Arthritis Rheum 2013;65:314–24.
    OpenUrlCrossRefPubMed
  3. 3.↵
    1. Mandel DE,
    2. Malemud CJ,
    3. Askari AD
    . Idiopathic inflammatory myopathies: a review of the classification and impact of pathogenesis. Int J Mol Sci 2017;18:1084.
    OpenUrl
  4. 4.↵
    1. Bohan A,
    2. Peter JB
    . Polymyositis and dermatomyositis. N Engl J Med 1975;292:344–7.
    OpenUrlCrossRefPubMed
  5. 5.↵
    1. Winthrop KL,
    2. Mariette X,
    3. Silva JT,
    4. Benamu E,
    5. Calabrese LH,
    6. Dumusc A,
    7. et al.
    ESCMID Study Group for Infections in Compromised Hosts (ESGICH) Consensus Document on the safety of targeted and biological therapies: an infectious diseases perspective (Soluble immune effector molecules [II]: agents targeting interleukins, immunoglobulins and complement factors). Clin Microbiol Infect 2018;24 Suppl 2:S21–40.
    OpenUrl
  6. 6.↵
    1. Lahoria R,
    2. Selcen D,
    3. Engel AG
    . Microvascular alterations and the role of complement in dermatomyositis. Brain 2016;139:1891–903.
    OpenUrlCrossRefPubMed
  7. 7.↵
    1. Pytel P
    . C4d staining as immunohistochemical marker in inflammatory myopathies. Appl Immunohistochem Mol Morphol 2014;22:696–704.
    OpenUrl
  8. 8.↵
    1. Couvrat-Desvergnes G,
    2. Masseau A,
    3. Benveniste O,
    4. Bruel A,
    5. Hervier B,
    6. Mussini JM,
    7. et al.
    The spectrum of renal involvement in patients with inflammatory myopathies. Medicine 2014;93:33–41.
    OpenUrl
  9. 9.↵
    1. Hofer J,
    2. Rosales A,
    3. Fischer C,
    4. Giner T
    . Extra-renal manifestations of complement-mediated thrombotic microangiopathies. Front Pediatr 2014;2:97.
    OpenUrl
  10. 10.↵
    1. Licht C,
    2. Greenbaum LA,
    3. Muus P,
    4. Babu S,
    5. Bedrosian CL,
    6. Cohen DJ,
    7. et al.
    Efficacy and safety of eculizumab in atypical hemolytic uremic syndrome from 2-year extensions of phase 2 studies. Kidney Int 2015;87:1061–73.
    OpenUrlCrossRefPubMed
  11. 11.↵
    1. Takada K,
    2. Bookbinder S,
    3. Furie R,
    4. Oddis C,
    5. Mojcik C,
    6. Bombara M,
    7. et al.
    A pilot study of eculizumab in patients with dermatomyositis. Arthritis Rheum 2002;46 Suppl 9:S489.
    OpenUrlCrossRef
View Abstract
PreviousNext
Back to top

In this issue

The Journal of Rheumatology
Vol. 45, Issue 12
1 Dec 2018
  • Table of Contents
  • Table of Contents (PDF)
  • Index by Author
  • Editorial Board (PDF)
Print
Download PDF
Article Alerts
Sign In to Email Alerts with your Email Address
Email Article

Thank you for your interest in spreading the word about The Journal of Rheumatology.

NOTE: We only request your email address so that the person you are recommending the page to knows that you wanted them to see it, and that it is not junk mail. We do not capture any email address.

Enter multiple addresses on separate lines or separate them with commas.
Complement C5-blocking Agent in Refractory Dermatomyositis
(Your Name) has forwarded a page to you from The Journal of Rheumatology
(Your Name) thought you would like to see this page from the The Journal of Rheumatology web site.
Citation Tools
Complement C5-blocking Agent in Refractory Dermatomyositis
STANISLAS FAGUER, JULIE BELLIERE, DAVID RIBES
The Journal of Rheumatology Dec 2018, 45 (12) 1710-1711; DOI: 10.3899/jrheum.180060

Citation Manager Formats

  • BibTeX
  • Bookends
  • EasyBib
  • EndNote (tagged)
  • EndNote 8 (xml)
  • Medlars
  • Mendeley
  • Papers
  • RefWorks Tagged
  • Ref Manager
  • RIS
  • Zotero

 Request Permissions

Share
Complement C5-blocking Agent in Refractory Dermatomyositis
STANISLAS FAGUER, JULIE BELLIERE, DAVID RIBES
The Journal of Rheumatology Dec 2018, 45 (12) 1710-1711; DOI: 10.3899/jrheum.180060
del.icio.us logo Digg logo Reddit logo Twitter logo CiteULike logo Facebook logo Google logo Mendeley logo
  • Tweet Widget
  • Facebook Like
  • Google Plus One
Save to my folders

Jump to section

  • Article
    • To the Editor:
    • REFERENCES
  • Figures & Data
  • References
  • Info & Metrics
  • PDF
  • eLetters

Related Articles

Cited By...

More in this TOC Section

  • A Case of Minimal Change Disease in a Patient with Rheumatoid Arthritis Treated with Certolizumab
  • Acute Myocarditis in Patients with Antineutrophil Cytoplasmic Antibody–positive Microscopic Polyangiitis and Receiving Rituximab Therapy
  • The Performance of Psoriatic Arthritis Screening Questionnaires in Patients with Psoriasis
Show more Letter

Similar Articles

Content

  • First Release
  • Current
  • Archives
  • Collections
  • AV Rheum

Resources

  • Guide for Authors
  • Submit Manuscript
  • Author Payment
  • Reviewers
  • Advertisers
  • Classified Ads
  • Reprints and Translations
  • Permissions
  • Meetings
  • FAQ
  • Policies

Subscribers

  • Subscription Information
  • Purchase Subscription
  • Your Account
  • Terms and Conditions

More

  • About Us
  • Contact Us
  • My Alerts
  • My Folders
  • RSS Feeds
The Journal of Rheumatology
The content of this site is intended for health care professionals.
Copyright © 2016 by The Journal of Rheumatology Publishing Co. Ltd.
Print ISSN: 0315-162X; Online ISSN: 1499-2752
Powered by HighWire